NCT04493684View on ClinicalTrials.gov

GSK3739937 First-Time-In-Human (FTIH) Study in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

July 31, 2020

Primary Completion Date

August 30, 2021

Study Completion Date

August 30, 2021

Conditions
HIV Infections
Interventions
DRUG

GSK3739937 (PIB)

GSK3739937 will be administered as oral suspension.

DRUG

Placebo

Placebo will be given orally during each dosing day.

DRUG

GSK3739937 (Tablet)

GSK3739937 Tablet will be administered via oral route.

Trial Locations (1)

21225

GSK Investigational Site, Baltimore

Sponsors

Lead Sponsor

ViiV Healthcare
All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY